What Life Intelligence Consortium does

Life Intelligence Consortium (LINC) is a Japan-based general incorporated association (ippan shadan hojin / 一般社団法人) that operates an industry-academia consortium applying artificial intelligence and big data analytics to drug discovery and life sciences research. Headquartered in Osaka and led by Representative Director Okuno Yasufumi (奥野恭範), the organization was founded as a project in November 2016 and formally incorporated in January 2021. Its membership comprises 16 pharmaceutical companies that collaborate through multiple working groups spanning drug discovery, digital health, agrochemical applications (AgriAI), generative AI, and predictive analytics.

LINC's core offering is a federated learning AI drug discovery platform that the organization describes as the world's first commercially deployed federated learning system. The platform trains multiple AI models on data contributed by member pharmaceutical companies without requiring raw data to leave member organizations, addressing data confidentiality and competitive constraints that have historically limited cross-pharma data collaboration. The consortium supplements platform development with recurring showcase events and an expanding portfolio of working groups that extend the federated learning approach beyond small-molecule drug discovery into adjacent life sciences domains. The organization maintains a strategic technology partnership with Elix Inc. and received the 36th Momofuku Ando Award in 2024, awarded to its Representative Director.

The organization operates as a non-profit membership-based consortium, with revenue generated through member dues from its 16 pharmaceutical company members; no membership pricing, ARR figures, or financial disclosures are publicly available. Participation in international venues such as ISPOR Europe 2025 in Glasgow indicates an intent to broaden awareness beyond the Japan-centric member base, though the consortium's revenue mechanics remain bounded by its non-profit structure and closed membership model.

Name

Life Intelligence Consortium

Legal name

Life Intelligence Consortium

Website

https://linc-ai.jp

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Life Intelligence Consortium (LINC) is a Japan-based non-profit consortium of 16 pharmaceutical companies operating a federated learning AI drug discovery platform, headquartered in Osaka and led by Representative Director Okuno Yasufumi (奥野恭範).

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Federated learning
• AI drug discovery
• Pharmaceutical consortium
• Life sciences AI
• Big data analytics

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Membership-based consortium: LINC operates as a general incorporated association ( 一般社団法人 ) funded by member organizations from the life sciences and pharmaceutical industries. The consortium conducts collaborative research and development in AI, big data, and IoT for life sciences applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Life Intelligence Consortium (LINC) operates as a Japan-based industry-academia consortium that developed and commercialized (with Elix Inc.) the world's first AI drug discovery platform using federated learning to train AI models on data from 16 pharmaceutical companies without exposing raw proprietary data. The consortium also coordinates multiple domain-specific Working Groups covering digital health/real-world data, medicinal chemistry, ADMET/translational research, clinical trials/post-marketing, and human resource development.

Product overview

Life Intelligence Consortium (LINC) is a general incorporated association focused on AI × Big Data × Life Sciences. The organization operates as a consortium structure with multiple Working Groups (WGs) conducting research and development in specific domains including digital health and real-world data analysis (WG01), medicinal chemistry/AgriAI (WG05), ADMET/translational research (WG07), clinical trials/post-marketing/medical affairs (WG08), and human resource development (WG09). LINC's flagship product is the AI Drug Discovery Platform, developed in partnership with Elix, which utilizes federated learning technology to enable pharmaceutical companies to collaboratively train AI models while keeping their proprietary data private.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Drug Discovery Platform (AI創薬プラットフォーム) An AI-powered drug discovery platform developed jointly by LINC and Elix that uses federated learning to train AI models on combined data from 16 pharmaceutical companies while preserving data privacy, enabling collaborative drug discovery across the pharmaceutical industry.

Quantifiable outcome

• World's first commercialized AI drug discovery platform using federated learning with data from 16 pharmaceutical companies

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Partnerships

Six partnerships are on record, tiered core and supporting.

• Elix Inc. (株式会社Elix)coreStrategic or Co-development Partner · 8 July 2025Strategic partnership with Elix Inc. to commercialize the world's first AI drug discovery platform utilizing federated learning technology. LINC and Elix jointly developed the platform that enables multiple pharmaceutical companies to train AI models on their combined data without exposing individual proprietary data.
• 16 Pharmaceutical CompaniescoreStrategic or Co-development Partner · 8 July 2025Sixteen pharmaceutical companies participated in the federated learning initiative, providing data for collaborative AI model training for drug discovery. This consortium approach enables participating companies to leverage diverse datasets while maintaining data privacy.
• 京都대학교대학원 의학과 인간건강과학전공 대용량의학데이터과학분과 (Kyoto University Graduate School of Medicine, Department of Human Health Sciences, Big Data Medical Science)supportingOthersRelated organization providing academic research support and expertise in big data medical science
• 理化学研究所 건강살롱활羅艦 researches комплекс (RIKEN Health and Medical Science Initiative)supportingOthersRIKEN research complex providing institutional support for health and medical science research collaboration
• 의약기반·건강·영양연구소 (National Institute of Biomedical Innovation, Health and Nutrition)supportingOthersNational research institute supporting biomedical innovation and nutrition research
• 공공재단법인 도시활력연구소 (Urban Vitality Research Institute)supportingOthersResearch institute focused on urban vitality and its relationship to health and wellness

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Recursion Pharmaceuticals: Recursion is a leading AI drug discovery company using high-throughput biology and machine learning. While it operates as a commercial entity rather than a consortium, it represents a major alternative model for AI-driven pharma R&D competing for the same pharma AI budgets.
• Insitro: Insitro uses ML combined with high-throughput biology for drug discovery, with multi-year pharma partnerships (e.g., with Gilead, Bristol Myers Squibb). It represents the commercial single-company alternative to LINC's consortium approach.
• Schrödinger: Schrödinger provides physics-based computational chemistry and AI-driven drug discovery platforms used by major pharma companies. It is a well-established incumbent in computational life sciences and serves many of the same pharma customers as LINC.
• BenevolentAI: BenevolentAI combines AI with biomedical knowledge graphs for drug discovery, with pharma collaborations. It represents another commercial AI drug discovery platform competing for pharma AI engagement.
• Exscientia: Exscientia is an AI-driven precision medicine company with multiple pharma partnerships using AI for small molecule drug design. Comparable as a competing AI drug discovery platform seeking pharma partnerships.
• Tempus Labs: Tempus aggregates multi-source clinical and molecular data for AI-driven precision medicine and has pharma partnerships. Comparable as a multi-party data aggregation platform serving pharma R&D, though focused on clinical/molecular data rather than pre-clinical drug discovery.

Direct peers

• Owkin: Owkin operates a federated learning platform connecting hospitals and pharmaceutical companies for AI-driven drug discovery and clinical research. It is the most direct global analogue to LINC's federated learning model for life sciences, though Owkin is a venture-backed commercial company rather than a non-profit consortium.
• MELLODDY: MELLODDY was a 10-pharma consortium that ran the world's largest federated learning experiment for drug discovery in 2020. It is directly comparable to LINC's federated learning pharma consortium model, though it concluded as a project rather than an ongoing association.

Emerging players

• Atomwise: Atomwise uses AI for structure-based small molecule drug design with multiple pharma partnerships (e.g., Eli Lilly, Pfizer). Comparable as an emerging AI drug discovery player with consortium-style pharma collaborations.
• Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven drug discovery platforms combining quantum physics and ML. An emerging competitor in AI drug discovery addressing similar pharma data challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Intelligence Consortium